The higher the broader indexes go, the more conscious investors will be of investments that may offer defensive safety. Because of the essentiality of health-related services this makes medical stocks worth monitoring in this regard. Speaking to such, it's noteworthy that a slew of medical stocks are standing out among the Zacks Rank #1 (Strong Buy) list. Notably, here are a few of these highly-ranked medical stocks to consider for their growth and impressive price performances. New Strong Buy Stocks: HALO and NBIX The medical sector currently has 30 stocks that comprise spots on the Zacks Strong Buy list (231 total stocks) and Halozyme Therapeutics HALO and Neurocrine Biosciences NBIX are two of the new additions this week. HALO and NBIX have risen 40% in the last year and are two of the market’s top performers over the last decade soaring 442% and 920%, respectively. Far from the speculator growth phase, Halozyme is a biopharmaceutical company focused on treatments for oncology indications by targeting the tumor microenvironment while Neurocrine provides novel therapeutics for treating neuro-related diseases and disorders. Zacks Investment Research Image Source: Zacks Investment Research Halozyme’s valuation especially stands out, trading at 13.5X forward earnings with EPS projected to climb 41% this year to $3.90 compared to $2.77 a share last year. Better still, FY25 EPS is expected to increase by another 23%. Halozyme’s top line is forecasted to expand by double-digits as well with projections edging toward $1 billion. Zacks Investment Research Image Source: Zacks Investment Research Similarly, Neurocrine’s growth trajectory has been very compelling as total sales are slated to rise over 15% in FY24 and FY25 with projections over $2 billion. Neurocrine’s increased profitability is even more mesmerizing as EPS is expected to skyrocket 71% this year to $4.22 versus $2.47 a share in 2023. More impressive, FY25 EPS is projected to soar another 58% to $6.69. Plus, earnings estimate revisions have trickled higher over the last 60 days. Zacks Investment Research Image Source: Zacks Investment Research Haemonetics HAE Blood management solutions provider Haemonetics has been a recent fixture on the Zacks Rank #1 (Strong Buy) list, holding a spot since mid-June. While Haemonetics stock has been virtually flat in the last year, HAE is up 30% over the last two years and has very respectable decade gains of 141%. Interestingly enough, this has been ample time to get in on Haemonetics stock at an attractive forward earnings multiple of 18.4X which is pleasantly beneath its decade-long high of 53.8X and a 28% discount to the median of 25.8X. Zacks Investment Research Image Source: Zacks Investment Research Furthermore, Haemonetics is expecting double-digit EPS growth in its current FY25 and FY26. Serving as a viable long-term investment, Haemonetics’ integrated devices, information management, and consulting services cover each facet of the blood supply chain for clinics and hospitals. Zacks Investment Research Image Source: Zacks Investment Research Bottom Line The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list. Considering their impressive decade performances and continued expansion, Halozyme Therapeutics, Neurocrine Biosciences, and Haemonetics are three of these highly-ranked medical stocks that should be at the forefront of investors' attention. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE):Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO):Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Top Medical Stocks to Buy for Growth & Performance
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...